Open AccessWhat Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?
Author(s) -
Patrick B. Schwartz,
Christopher C. Stahl,
Kara A. Vande Walle,
Courtney Pokrzywa,
Linda Stafford,
Taylor Aiken,
James Barrett,
Alexandra W. Acher,
Glen Leverson,
Sean Ronnekleiv-Kelly,
Sharon M. Weber,
Daniel E. Abbott
Publication year - 2020
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-020-08583-7
Subject(s) - surgical oncology , medicine , cytoreductive surgery , general surgery , surgery , cancer , ovarian cancer
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is utilized for peritoneal malignancies and is associated with significant resource use. To address potentially modifiable factors contributing to excessive cost, we sought to determine predictors of high cost of care for patients undergoing CRS/HIPEC.